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Abstract
Background: The ability to detect neoplasia-specific fusion genes is important not only in cancer
research, but also increasingly in clinical settings to ensure that correct diagnosis is made and the
optimal treatment is chosen. However, the available methodologies to detect such fusions all have
their distinct short-comings.
Results: We describe a novel oligonucleotide microarray strategy whereby one can screen for all
known oncogenic fusion transcripts in a single experiment. To accomplish this, we combine
measurements of chimeric transcript junctions with exon-wise measurements of individual fusion
partners. To demonstrate the usefulness of the approach, we designed a DNA microarray
containing 68,861 oligonucleotide probes that includes oligos covering all combinations of chimeric
exon-exon junctions from 275 pairs of fusion genes, as well as sets of oligos internal to all the exons
of the fusion partners. Using this array, proof of principle was demonstrated by detection of known
fusion genes (such as TCF3:PBX1, ETV6:RUNX1, and TMPRSS2:ERG) from all six positive controls
consisting of leukemia cell lines and prostate cancer biopsies.
Conclusion: This new method bears promise of an important complement to currently used
diagnostic and research tools for the detection of fusion genes in neoplastic diseases.
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Fusion genes created by structural chromosomal rear-
rangements such as translocations, deletions, and inver-
sions are often the pathogenetically essential feature of
cancer genomes. They seem to be particularly characteris-
tic of hematological malignancies and sarcomas, where
their identification may be crucial for differential diagno-
sis and therapeutic decision-making. Fusion genes have so
far been found less frequently in the common solid can-
cers, but recent reports on prostate and lung carcinomas
show that fusion transcripts may contribute significantly
also to the development of these malignancies [refs. [1-3];
reviewed in [4,5]].
The detection of fusion genes in cancer is laborious and
time-consuming and usually includes chromosome band-
ing analysis (karyotyping) followed by fluorescence in situ
hybridization (FISH) studies and molecular analyses
based on the reverse transcriptase polymerase chain reac-
tion (RT-PCR). Karyotyping requires the availability of
fresh, vital cells for short-term culturing to obtain met-
aphase chromosomes, and the success rate of this
approach may be particularly low for solid tumors. In
addition to taking a lot of time, the method also requires
highly trained and experienced personnel to interpret the
karyotypes correctly and identify whatever rearrange-
ments may exist. The main advantage of the approach is
that it is global in nature; it screens without prejudice for
all rearrangements at the chromosomal resolution level.
FISH with locus-specific probes and RT-PCR, on the other
hand, are precise and highly specific methods used for the
analysis of one or a few candidate fusion genes at prede-
fined breakpoints; the approach is therefore dependent
on prior knowledge of the suspected diagnosis. The specif-
icity of these methods at the same time highlights their
main limitation; they have no screening ability.
Recent developments of high-throughput sequencing
technologies enable genome-wide identification of novel
fusion transcripts at an unprecedented level of resolution
[6-9], but these technologies are as yet limited by the
number of samples that can be analyzed within a reason-
able time-frame and at an acceptable cost. A few studies
have utilized oligo microarrays targeting junction
sequences to detect fusion transcripts [10-13]. They have
then relied on preceding amplification of a small selection
of fusion transcripts by RT-PCR, thus limiting the coverage
offered by these approaches to a predefined set of fusion
junction sequences.
In this report, we present a new oligo microarray-based
approach for simultaneous analysis of all known or pre-
dicted fusion gene variants, with all possible chimeric
exon-exon junction combinations. The analysis can be
performed in a single experiment and does not include
prior sequence-specific amplification.
Methods
Cell lines and biopsies
To test our novel method for fusion gene detection, we
selected four prostate cancer samples (fresh frozen tissue
obtained from prostatectomy specimens of four inde-
pendent patients) and two leukemic cell lines, all known
to harbor a specific fusion gene. The cell lines, RCH-ACV
[14] and REH [15,16], are of human B-cell precursor
leukemia origin and were provided by Dr. Edith Rian.
Preparation of cDNA for microarray analysis and RT-PCR
Total RNA was isolated using the Trizol reagent (Life Tech-
nologies, Rockville, MD, USA), and the RNA quality was
evaluated by use of the Agilent 2100 Bioanalyzer (Agilent
Technologies, Palo Alto, CA, USA). To enrich for messen-
ger RNA, we used the RiboMinus kit (Invitrogen,
Carlsbad, CA, USA) which subtracts ribosomal RNA from
total RNA. To ensure detection of fusion junctions far
away from the poly-A tail, the first strand cDNA was pre-
pared by random priming to avoid the 3' end bias intro-
duced by oligo-dT labeling. Double stranded cDNA was
labeled and hybridized onto the oligo microarrays.
Microarray design
We set up a database with a broad coverage of the reported
fusion genes in cancer (351 to date), including informa-
tion on which of the fusion partners are up- and down-
stream in the majority of the resulting fusion transcripts.
See Additional file 1 for the identities and orientation of
the 275 fusion genes included in the pilot microarray
design. We used public genome sequence information
from Biomart to extract the exon sequences of all listed
transcript variants [17].
A script was written in the programming language Python
for design of the oligos. For genes that constitute the 5'
portion of fusion genes, we used the 3' end-sequences of
the exons when constructing chimeric fusion junction oli-
gos. For genes that are the 3' portion of fusion genes, we
used the 5' start-sequences of the exons. Thus, for each
fusion gene, we joined and listed all combinations of end-
sequences and start-sequences. These chimeric sequences
served as input for the design of chimeric fusion junction
oligos, enabling detection of any breakpoint combination
in the fusion genes. Chimeric oligos were constructed tar-
geting all possible combinations of chimeric exon junc-
tions between the up- and downstream partners of 275
known fusion genes. For a set of fusion genes, including
the ones known to be present in the control samples, we
extended the design to include four replicates of each of
the exon-exon junctions, as well as altogether four extra
control oligos for each exon-exon junction (oligos up-
and down-shifted by two nucleotides as compared to the
standard ones). Furthermore, a series of intragenic oligos
were designed for measurements of longitudinal profiles
of each of the fusion gene partners of altogether 115Page 2 of 9
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These were oligos targeting the start, mid, and end part of
all exons and all introns, as well as oligos targeting the
exon-exon, exon-intron, and intron-exon junctions. The
exon-intron junctions and intron-exon junctions are also
included among the single-gene oligos, as the pre-mRNA
processing machinery may alter the splicing pattern fol-
lowing removal or introduction of cis-acting splicing reg-
ulatory sequences.
The constructed microarray included a design with 68,861
oligos, including 59,381 chimeric oligos (of which 55,482
were unique), which were synthesized onto custom-pro-
duced NimbleGen microarray slides (Roche NimbleGen,
Inc., Madison, WI, USA). The chimeric oligos were
designed to optimize for similar melting temperatures on
each side of the junctions, thus reducing half-binder
effects.
Two versions of the microarray were designed, differing as
to the probe lengths. The set of shorter oligos, with
lengths ranging from 34 to 40-mers, had a Tm optimum
of 72°C. The set of longer oligos, with lengths ranging
from 44 to 50-mers, had a Tm optimum of 75°C. All sam-
ples, except the REH cell line, were hybridized onto the
short-oligo microarray, whereas the RCH-ACV and REH
cell lines were hybridized onto the long-oligo microarray.
The cell line RCH-ACV was analyzed by both microarray
designs, and data from its positive control gene,
TCF3:PBX1, demonstrated best performance of the short
oligos due to substantial half-binder signals with the
longer oligos (data not shown).
Because of the relatively short length of the sequences on
each side of the junction, the binding may be sensitive to
single nucleotide polymorphisms (SNPs). Thus, at known
SNP positions, we created extra sets of probes, accounting
for each of the SNP variants.
Data preprocessing and annotation
Data preprocessed by NimbleGen were further normal-
ized by dividing all individual probe intensity values for
each of the samples by the median of the three leukemia
cell lines. We normalized based on these three samples
(instead of all samples) because when the majority of the
samples contain the same fusion gene and breakpoint
(TMPRSS2:ERG, e1:e4), normalizing on all samples
would level out the appearance of this fusion event in the
dataset.
All oligonucleotide probes were mapped to their one or
two respective genomic loci. For each locus, the Ensembl
identifiers for exon (ENSE), transcript (ENST), and gene
(ENSG) identities were used.
Raw and processed data were deposited to the Gene
Expression Omnibus public repository for microarray
data [accession number GSE14435] according to the
MIAME, minimum information about a microarray exper-
iment, recommendations for recording and reporting
microarray-based gene expression data [18].
Automated scoring algorithm
Downstream fusion partners will generally have higher
expression values for exons downstream of the fusion
breakpoint. For each exon-exon junction of downstream
fusion partner genes, two probabilities were calculated.
One probability was based on a t-test for whether values
from all upstream and all downstream exons are likely to
belong to different populations. A second probability was
based on a t-test for whether the values from the immedi-
ate up- and downstream exons are likely to belong to dif-
ferent populations.
A fusion score was calculated as the product of the nor-
malized expression value for the chimeric oligo and the
probabilities of the exon-exon junction of the correspond-
ing position in the downstream fusion partner being a
breakpoint in the longitudinal profile [Fusion score = Chi-
meric junction score * P(B-gene transcript) * P(B-gene
exon)].
To keep the values within scale, the following thresholds
were applied: when the normalized values for chimeric
oligos were larger than 5, they were set to 5 (approxi-
mately 5 per 10,000 values). Similarly, when probabilities
for a breakpoint in the longitudinal profiles were < 0.10,
they were set to 0.10. When the values from the down-
stream exons were lower than the values from the
upstream exons, the probability was set to 0.10 as well.
Experimental validation of fusion transcript breakpoints
We used RT-PCR followed by DNA sequencing to validate
the actual fusion junctions in the positive control fusion
genes. The following primers were applied: TCF3:PBX1:
TCF3, exon 15, forward, 5'-CACCCTCCCTGACCTGTCT-
3', and PBX1, exon 3, reverse, 5'-TGCTCCACTGAGTT-
GTCTGAA-3'; yielding a chimeric fusion product of 218
basepairs. ETV6:RUNX1: ETV6, exon 5, forward, 5'-
CACTCCGTGGATTTCAAACA-3', and RUNX1, exon 2,
reverse, 5'-CGTGGACGTCTCTAGAAGGA-3'; yielding a
chimeric fusion product of 204 basepairs. TMPRSS2:ERG
[as published in ref. [19]]: TMPRSS2, exon 1, forward, 5'-
TAGGCGCGAGCTAAGCAGGAG-3', and ERG, exon 6,
reverse, 5'-CTGCCGCACATGGTCTGTAC-3'; yielding a
chimeric fusion product of 597 basepairs. The PCR prod-
ucts were separated by gel electrophoresis in a 2% agarose
gel. For all fusion genes, DNA was isolated from the
appropriate PCR bands (MiniElute Gel Extraction kit, Qia-Page 3 of 9
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tions using the same primers as for the RT-PCR (ABI Prism
3730; Applied Biosystems, Foster City, CA, USA).
Cytogenetics
Cell cultures from the leukemia cell lines were harvested
for chromosome banding analysis. Chromosome prepa-
rations were made and G-banded using trypsin (DIFCO
Laboratories, Detroit, MI, USA) and Leishman staining
(BDH, Poole, England). For metaphase FISH, commer-
cially available probes for the TCF3:PBX1 (TCF3 FISH
DNA probe, split signal, DAKO Denmark A/S, Glostrup,
Denmark) and ETV6:RUNX1 (dual color, Dual Fusion
Translocation Probe Set; Vysis, Abbott Laboratories,
Abbott Park, IL, USA) fusion genes were used. The dena-
turation and hybridization conditions as well as the sub-
sequent detection procedures were in accordance with the
manufacturers' protocols. Two hundred successive,
whole, and single nuclei were examined through a Zeiss
fluorescence microscope (Zeiss Axioplan, Oberkochen,
Germany) for each FISH experiment.
Results
We have developed a novel strategy for the detection of
oncogenic fusion transcripts enabling simultaneous anal-
ysis of all known or predicted fusion gene variants, with
all possible chimeric exon-exon junction combinations
targeting each possible fusion gene junction on the proc-
essed mRNA level (Figure 1). We combine the use of chi-
meric oligos, spanning the two potential fusion gene
partners, with the use of single-gene oligos that provide
measurements along the length of each individual part-
ner.
We analyzed cDNA from a set of six positive control sam-
ples with known presence of one fusion gene in each. This
included two leukemia cell lines, RCH-ACV and REH,
known to carry the TCF3:PBX1 and ETV6:RUNX1 fusion
genes, respectively, and four prostate cancer samples pos-
itive for the TMPRSS2:ERG fusion gene.
To combine the information from the chimeric junction
measurements with that of the longitudinal intragenic
profiles, a fusion score was calculated for all fusion tran-
scripts and their respective breakpoints (details in Materi-
als and Methods). This enabled an objective and
automated evaluation of the presence of fusion genes, and
the fusion score was calculated for 10,297 possible fusion
events. The positive control fusion transcripts, with their
correct breakpoint positions, was ranked as the number
one hit in four out of the five samples run on the short-
oligo microarray (Figures 2A and 3A), thus validating the
concept. For prostate cancer sample P140, the expected
TMPRSS2 exon 1:ERG exon 4 fusion gene was assigned a
fusion score rank of 95 within the 10,297 fusion break-
points (and number one within the 154 measured junc-
tions of TMPRSS2:ERG). When dissecting the values
behind the fusion score for this positive control, we see
that the intensity of the chimeric oligo was particularly
low. This is also in compliance with RT-PCR results from
the prostate cancer samples, demonstrating that this sam-
ple had a low expression level of the fusion gene as com-
pared to the other samples (data not shown).
To evaluate the top fusion score hits and positive control
fusion genes further, we visualized them via two inde-
pendent paths, using either the chimeric probe set (Fig-
ures 2B and 3B) or the longitudinal intragenic probe set
(Figures 2C and 3C). The positive control fusion genes
were clearly visualized for all six analyzed samples.
Discussion
A novel microarray-based strategy is presented to screen
for all known oncogenic fusion transcripts in a given sam-
ple, combining measurements of chimeric transcript junc-
tions with exon-wise measurements of individual fusion
partners. This provides a viable alternative to the existing
cytogenetic and PCR-based methods for fusion gene
detection, as it enables an objective and automated
genome-wide analysis in which all known as well as pre-
dicted fusion genes are assessed without requiring any a
priori knowledge as to the likelihood of the clinical or
genetic diagnosis. Furthermore, the precise mapping
information on the fusion breakpoint is given within
every positive hit. Finally, the method is carried out in a
single experiment and does not include prior sequence-
specific amplification.
Because fusion breakpoints mainly map to intronic
sequences, the resulting fusion transcripts will, after pre-
mRNA processing, consist of whole exonic building
blocks. In fact, more than 90% of the mapped fusion
breakpoints are located in intronic sequences [20]. Thus,
independently of the intra-intronic location of the break-
points, a detection of all exon-exon junctions between
two fusion gene partners would in principle provide spe-
cific detection of fusion transcripts.
To our knowledge, this is the first time chimeric oligos tar-
geting fusion gene junctions have been used in combina-
tion with measurements of longitudinal profiles of the
individual fusion partners. Furthermore, the earlier publi-
cations on fusion gene measurements by oligo microar-
rays have not attempted to be genome-wide, restricting
their use to either a few pre-defined fusion junctions and
fusion genes [10-13] or to the exclusive use of intragenic
oligos [21]. Our pilot experiment alone included 68,861
oligos, and the current version of the NimbleGen micro-Page 4 of 9
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Microarray data for a positive fusion gene hitFigure 1
Microarray data for a positive fusion gene hit. (A) This theoretical example of a fusion gene has a crossing-over event 
between sequences in intron 2 of gene A and intron 3 of gene B. (B) If the genes A and B both have 10 exons, the microarray 
will contain 10 × 10 = 100 oligos to cover all chimeric exon-to-exon junction combinations for this particular fusion gene. The 
A2-B4 oligo detects the fusion transcript from part (A). (C) In true fusion events, the longitudinal profiles generated from intra-
genic oligos targeting each exon and exon-to-exon junction will provide independent confirmation.
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TCF3:PBX1 in a leukemia cell lineFigure 2
TCF3:PBX1 in a leukemia cell line. (A) The highest ranking fusion score (y-axis) among 10,297 chimeric combinations 
(ranked along the x-axis) indicated a fusion event between exons 16 and 3 of TCF3 and PBX1, respectively. (B) Fusion map of 
each chimeric exon-exon junction of TCF3 and PBX1. Intensities of red indicate the relative values of the medians for the four 
replicate oligos for each chimeric exon-exon junction, and the square with strongest intensity indicates the correct fusion 
breakpoint. (C) Measurements from intragenic oligos (intra-exon probes) for each of the two fusion partners are indicative of 
the same fusion breakpoints as seen from the chimeric oligos. (D) The exact fusion breakpoint between TCF3 and PBX1 was 
confirmed by cDNA sequencing. (E) Chromosome banding and fluorescence in situ hybridization analyses of the same cell line 
demonstrated rearranged chromosomes from the translocation t(1;19)(q23;p13), which implicates the loci of TCF3 and PBX1.
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Fusion gene plots for four individual prostate cancer samples with the same fusion eventigure 3
Fusion gene plots for four individual prostate cancer samples with the same fusion event. The four samples all had 
fusion transcripts with junctions between TMPRSS2 exon 1 and ERG exon 4. (A) Chimeric sequences plotted with increasing 
fusion scores. For the three first samples, the chimera of TMPRSS2:ERG exon1:4 had the highest ranking out of the 10,297 
tested combinations. (B) Fusion map of each chimeric exon-exon junction of TMPRSS2 and ERG. Intensities of red indicate the 
relative values of the medians for the four replicate oligos for each chimeric exon-exon junction and the white arrows point to 
the correct fusion breakpoints. (C) Measurements from intragenic oligos (intra-exon probes) for ERG demonstrate a shift in 
intensities between exons three and four.
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Molecular Cancer 2009, 8:5 http://www.molecular-cancer.com/content/8/1/5array platform enables analysis of up to 2.1 million oligos
on a single microarray slide. Thus, scaling up to include all
known fusion genes, as well as sets of novel candidate
fusion genes detected by high-throughput sequencing
strategies, can easily be achieved with the same resolution
level as the genes included in our pilot run.
Next-generation sequencing approaches are beginning to
provide numerous new pairs of fusion genes in individual
biological samples [6-9]. However, this methodology is
not feasible for screening purposes on large clinical sam-
ple series. The current microarray-based approach is suit-
able for assessing whether members of this growing set of
novel fusion transcripts (alongside with the already
known fusion genes) are indeed pathogenetic players in
the various subgroups of cancer.
The reported fusion gene detection platform can be used
irrespective of the tumor type in question. Detection of
certain fusion genes has direct diagnostic implications in
many leukemias and sarcomas, whereas other fusion
genes are more promiscuous and can be found in several
different cancer types. An example of the latter is the kary-
otypically cryptic translocation t(12;15)(p13;q25), result-
ing in the ETV6:NTRK3 fusion gene, which occurs in
histologically and developmentally completely disparate
tumors such as kidney and breast tumors, infantile fibro-
sarcoma, and acute myeloid leukemia [22].
Conclusion
We have developed a novel high throughput method for
detection of fusion genes with potentially significant
applications in cancer diagnostics. Also, for research
applications, there is a clear potential for detection of
putative fusion genes and discovery of already known
fusion genes in new cancer types.
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